Healthcare
•3762 stocks
•
Total Market Cap: Loading...
Nov 03, 2025
|
Tharimmune Raises $540 Million in Private Placement to Fund Digital Asset Treasury Strategy
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3762)
| Company | Market Cap | Price |
|---|---|---|
|
APM
Aptorum Group Limited
Aptorum plans near-term revenue from biopharma services via the DiamiR merger, aligning with contract research/Development outsourcing.
|
$7.88M |
$1.43
-1.04%
|
|
BMRA
Biomerica, Inc.
Biomerica directly manufactures diagnostic tests (inFoods IBS, hpdetect) and related software/equipment.
|
$7.85M |
$2.69
-3.41%
|
|
THAR
Tharimmune, Inc.
THAR directly develops monoclonal antibody therapeutics (e.g., TH023 and IO assets HS1940/HS3215), fitting Monoclonal Antibody Therapeutics.
|
$7.85M |
$3.21
+8.81%
|
|
ERNA
Ernexa Therapeutics Inc.
Lead product is off-the-shelf allogeneic cell therapy using iPSC-derived mesenchymal stem cells (iMSCs).
|
$7.82M |
$1.75
-7.18%
|
|
APRE
Aprea Therapeutics, Inc.
APRE is an oncology-focused biotech developing cancer therapies, namely DDR inhibitors, which aligns with Biotech - Oncology.
|
$7.74M |
$1.41
+0.71%
|
|
SCND
Scientific Industries, Inc.
Medical Devices & Biometrics – automated pharmacy hardware and other medical device equipment.
|
$7.74M |
$0.67
|
|
EVOK
Evoke Pharma, Inc.
Gimoti relies on a nasal drug-delivery platform/technology, making Drug Delivery Platforms a core investable theme for Evoke's product strategy.
|
$7.69M |
$4.71
-8.64%
|
|
TRIB
Trinity Biotech plc
Directly manufactures glucose monitoring hardware (CGM) and wearable biosensors with an accompanying data platform.
|
$7.67M |
$1.01
+1.50%
|
|
LCTC
Lifeloc Technologies, Inc.
Lifeloc Technologies manufactures breath alcohol testing devices, which are diagnostic instruments used for disease detection and monitoring.
|
$7.66M |
$3.12
|
|
LYRA
Lyra Therapeutics, Inc.
XTreo drug-delivery platform is Lyra's core product, enabling six months of localized drug therapy via in-office implant (LYR-210).
|
$7.63M |
$6.04
+4.77%
|
|
PAVM
PAVmed Inc.
EsoGuard and EsoCheck are proprietary diagnostic devices/tests used for esophageal precancer detection, a direct diagnostic equipment product line.
|
$7.56M |
$0.40
-5.99%
|
|
BCTX
BriaCell Therapeutics Corp.
BriaCell develops off-the-shelf allogeneic cell therapies (Bria-IMT) and a cell-therapy platform (Bria-OTS).
|
$7.45M |
$9.82
-10.73%
|
|
SSKN
STRATA Skin Sciences, Inc.
STRATA's core offerings are dermatology-focused excimer laser systems and related medical devices (XTRAC, Pharos lasers; VTRAC lamp systems; TheraClear X), which are medical devices and equipment.
|
$7.42M |
$1.72
-3.65%
|
|
ALZN
Alzamend Neuro, Inc.
Company's pipeline includes Alzheimer's disease therapeutics (ALZN002) and a focused strategy on Alzheimer's treatment.
|
$7.33M |
$2.41
-4.74%
|
|
BCDA
BioCardia, Inc.
CardiAMP and CardiALLO are BioCardia's direct cell-therapy programs (autologous and allogeneic) targeted for cardiovascular disease.
|
$7.25M |
$1.42
+1.07%
|
|
NLSP
NLS Pharmaceutics AG
Kadimastem's allogeneic cell-therapy platform (IsletRx, AstroRx) and NLSP's merger create a clear Cell Therapy business line.
|
$7.19M |
$0.79
-89.59%
|
|
ADXN
Addex Therapeutics Ltd
Addex's core product category is oral small-molecule therapeutics (allosteric modulators including GABAB PAMs and mGluR modulators).
|
$7.17M |
$9.29
+2.03%
|
|
KPRX
Kiora Pharmaceuticals, Inc.
Company's pipeline focuses on ophthalmic therapeutics (KIO-301, KIO-104) targeting retinal degenerative diseases and retinal inflammation, i.e., Ophthalmic Drugs.
|
$7.03M |
$2.42
+4.76%
|
|
CDIO
Cardio Diagnostics Holdings, Inc.
Provides laboratory testing services and advisory support for diagnostics.
|
$7.02M |
$4.40
+8.91%
|
|
VASO
Vaso Corporation
Vaso develops and sells medical devices and biometrics-related technology (cardiovascular focus).
|
$6.87M |
$0.11
|
|
LFWD
Lifeward Ltd.
LFWD directly designs, manufactures, and sells medical devices (exoskeletons, anti-gravity systems, and rehabilitation solutions), fitting Medical Devices & Biometrics.
|
$6.80M |
$0.58
-5.26%
|
|
ENTO
Entero Therapeutics, Inc.
Adrulipase is a recombinant lipase enzyme produced as a therapeutic for exocrine pancreatic insufficiency, fitting Recombinant Proteins & Enzymes.
|
$6.75M |
$4.12
-3.18%
|
|
INBS
Intelligent Bio Solutions Inc.
INBS directly develops and sells the Intelligent Fingerprinting Platform, a diagnostic device for non-invasive drug screening (fingerprint sweat-based testing) and associated cartridges/readers.
|
$6.75M |
$0.92
-5.99%
|
|
GBCS
Selectis Health, Inc.
Operational healthcare facilities providing in-patient care aligns with Hospital Services as a proxy for healthcare facility operations.
|
$6.72M |
$2.20
|
|
NBY
NovaBay Pharmaceuticals, Inc.
Directly manufactures wound care devices which are the sole continuing reportable product line (export to China).
|
$6.69M |
$1.11
-3.04%
|
|
DQWS
DSwiss, Inc.
DQWS provides turnkey OEM/ODM contract manufacturing services for health care, beauty, and nutraceutical products.
|
$6.62M |
$0.03
|
|
MBRX
Moleculin Biotech, Inc.
Moleculin Biotech's lead asset Annamycin is a cancer drug candidate, placing the company squarely in the Biotech - Oncology category.
|
$6.57M |
$0.51
+8.70%
|
|
SNOA
Sonoma Pharmaceuticals, Inc.
Company offers HOCl-based wound care products that function as wound care solutions/devices.
|
$6.47M |
$3.92
-0.51%
|
|
IBO
Impact BioMedical Inc.
Linebacker is an oncology-focused platform of electrophilically enhanced polyphenol compounds licensed for development and commercialization.
|
$6.47M |
$0.53
-1.66%
|
|
PMCB
PharmaCyte Biotech, Inc.
PMCB's encapsulation technology is a drug-delivery platform enabling localized prodrug activation.
|
$6.38M |
$0.91
-2.15%
|
Showing page 35 of 38 (3762 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
